Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registries

Table 2 Baseline demographics and clinical characteristics of patients with RA in the post-marketing epidemiology abatacept study

	ATTRA	DANBIO	ROB-FIN	ORA	GISEA	BIOBADASER	SCQM^a
Number of patients	335	1213	362	976	433 with 770^b total reported events	350	959 infection cohort 1053 malignancy cohort
Patient-years of exposure	862	4513	530	6119	NR	NR	1902 infection cohort 3683 malignancy cohort
Age (years), mean (SD)	52.1 (11.4)	57.2 (12.7)	54.7 (13.5)	58.0 (14.0)	First-line: 58.1 (NR) Second-line: 58.5 (NR) Other lines: 57.5 (NR)	57.5 (13.5)	58 (13)
Female, n (%)	270 (81)	941 (78)	308 (85)	771 (79)	654 (85)	276 (79)	~ 79%
Duration of RA (years), mean (SD)	8.1 (7.4)	10.1 (9.9)	12.8 (11.0)	14.0 (10.0)	First-line: 9.2 (NR) Second-line: 11.3 (NR) Other lines: 13.3 (NR)	NR	~ 11 (NR)

ATTRA Anti-TNF Therapy in Rheumatoid Arthritis, BIOBADASER Spanish Register of Adverse Events of Biological Therapies in Rheumatic Diseases, DANBIO Danish Rheumatologic Database, GISEA Italian Group for the Study of Early Arthritis, NR not reported, ORA Orencia and Rheumatoid Arthritis, RA rheumatoid arthritis, ROB-FIN National Registry of Biological Treatment in Finland, SCQM Swiss Clinical Quality Management, SD standard deviation
^aPatient populations differed for the different outcomes; baseline characteristics of the patient populations for each outcome were similar
^bTotal for first-line, second-line, and other lines of treatment from 2007 to November 2015

ISSN: 1478-6362